Digital transformation directly affects GMP compliance requirements by introducing new obligations around data integrity, system validation, and electronic record management. As pharmaceutical companies adopt cloud platforms, AI-driven analytics, and automated manufacturing systems, regulators expect the same level of control and traceability that applies to paper-based processes, but applied to digital environments. The sections below address the most common compliance questions that arise during a digital rollout.
What GMP requirements apply to digital systems in pharma?
GMP requirements apply to any digital system that creates, modifies, stores, or transmits data related to the manufacture, testing, or release of medicinal products. This includes manufacturing execution systems, laboratory information management systems, electronic batch records, and quality management software. The core regulatory frameworks are EU GMP Annex 11 in Europe and FDA 21 CFR Part 11 in the United States, both of which set binding expectations for electronic records and electronic signatures.
These frameworks require companies to demonstrate that digital systems are fit for purpose, properly validated, and protected against unauthorized access or data loss. Key obligations include audit trails that capture who changed what and when, access controls that restrict system functions to authorized users, and backup and recovery procedures that protect data from corruption or loss. Any system used in a GMP context must also be covered by a formal supplier assessment if it is provided by a third party, since the marketing authorization holder retains ultimate responsibility for compliance regardless of where the system is hosted. To learn more about how Starodub approaches these challenges, visit our services overview.
How does digital transformation change data integrity obligations?
Digital transformation intensifies data integrity obligations because electronic data is inherently easier to alter, delete, or replicate than paper records, and regulators are acutely aware of this risk. The ALCOA+ principles, which require data to be Attributable, Legible, Contemporaneous, Original, and Accurate, apply to electronic records exactly as they do to handwritten ones, and in some respects the bar is higher because audit trails must be automatic and tamper-evident rather than relying on manual controls.
When companies move from paper to digital workflows, they must map every data flow and identify where critical GMP data is generated, processed, and stored. Hybrid environments, where paper and electronic records coexist, are particularly risky because gaps between the two can create opportunities for data to be entered retrospectively or inconsistently. Regulators have issued repeated guidance, including from the EMA and WHO, emphasizing that a digital system does not automatically improve data integrity; it simply changes where the vulnerabilities lie. Companies must conduct a data integrity risk assessment as part of any digital transformation project.
Which digital technologies pose the highest GMP compliance risk?
Cloud-based systems, artificial intelligence tools used in manufacturing or quality decisions, and Internet of Things devices connected to production equipment carry the highest GMP compliance risk because they introduce complexity, external dependencies, and novel failure modes that traditional validation approaches were not designed to address.
Cloud platforms raise questions about data residency, access by the cloud provider, and the company’s ability to retrieve and migrate data if the vendor relationship ends. AI and machine learning systems used to make or support batch release decisions introduce the challenge of algorithm transparency, since a model that updates itself over time may behave differently from the version that was originally validated. IoT sensors and connected equipment create large volumes of automated data, which must be captured in a way that satisfies audit trail requirements and can be reviewed meaningfully during an inspection. Each of these technologies requires a specific risk assessment before deployment in a GMP environment.
What is computer system validation and why is it still required?
Computer system validation, often abbreviated as CSV, is the documented process of demonstrating that a computerized system consistently performs its intended function in a GMP environment and produces reliable, accurate results. It is still required because regulators need evidence that a system is fit for its intended use before it is relied upon to generate or manage data that affects product quality or patient safety.
The traditional CSV approach involves creating a validation plan, defining user requirements, testing against those requirements, and producing a summary report. In 2022, the International Society for Pharmaceutical Engineering published a new framework called Computer Software Assurance, which shifts the focus from generating documentation to performing meaningful testing based on risk. Regulators in both the EU and the US have acknowledged this shift, but the underlying obligation remains: companies must be able to demonstrate, with evidence, that their systems work as intended. For high-risk systems such as those controlling critical manufacturing parameters or generating batch release data, the depth of validation evidence required remains substantial.
How should companies manage GMP compliance during a digital rollout?
Companies should manage GMP compliance during a digital rollout by treating it as a change control event from the outset, applying formal risk assessment, validation planning, and training before the system goes live rather than retrofitting compliance after implementation.
A structured approach includes the following steps:
- Define the GMP impact category of the new system before procurement, since this determines the depth of validation and documentation required.
- Conduct a supplier audit or assessment to verify that the vendor’s quality management practices are compatible with GMP expectations.
- Establish a data migration plan if historical records are being transferred from a legacy system, ensuring the traceability and integrity of migrated data.
- Run parallel operations during the transition period where feasible, so that discrepancies between old and new systems can be identified before the legacy system is decommissioned.
- Train all affected personnel on the new system and document that training before the system is used in a live GMP context.
- Update SOPs and quality documentation to reflect the new workflows, including updated data integrity controls.
Rushing any of these steps to meet a project deadline is one of the most common causes of inspection findings related to digital systems.
What do regulators expect to see during GMP inspections of digital systems?
During GMP inspections, regulators expect to see documented evidence that every system used in a GMP context has been validated, that data integrity controls are technically enforced rather than relying solely on procedural measures, and that the company understands and manages the risks associated with its digital infrastructure.
Inspectors commonly request access to validation documentation, audit trail reviews, user access logs, and records of periodic system reviews. They will test whether audit trails are enabled, whether they capture all relevant changes, and whether they are routinely reviewed by quality personnel rather than left as passive records. Inspectors also look at how the company manages system changes, including software updates and configuration changes, to verify that these are handled through change control and do not invalidate prior validation work. A documented inventory of all GMP-relevant computerized systems, sometimes called a system register, is increasingly expected as a baseline during inspections.
How Starodub supports GMP compliance in digital environments
Navigating GMP compliance during digital transformation requires both regulatory expertise and practical experience with the systems and processes that regulators scrutinize. Our team at Starodub supports biopharmaceutical and medical device companies at every stage of this process, from initial system impact assessments through to inspection readiness.
Our support in this area includes:
- GMP impact assessments for new digital systems, including cloud platforms, AI tools, and automated manufacturing equipment
- Data integrity gap analyses aligned with EMA, FDA, and WHO guidance
- Computer system validation planning and documentation support, including alignment with current Computer Software Assurance approaches
- Change control guidance for digital rollouts and system upgrades
- Inspection preparation, including audit trail reviews and system register development
- Support from our Quality, Compliance and Operational Improvements division, led by Lean Six Sigma Master Black Belts with over 25 years of pharmaceutical industry experience
Whether you are implementing a new manufacturing execution system, migrating to a cloud-based quality platform, or preparing for a regulatory inspection, we provide the expert guidance you need to stay compliant. Contact Starodub today to discuss how we can support your digital transformation with confidence.
Related Articles
- What is early HTA dialogue and how does it affect market access?
- How does Brazil's ANVISA approval process work for foreign companies?
- Drug-Device Combination Products: Regulatory Framework Explained
- What comes first, IND or NDA?
- What is the difference between a CTA and IND submission?
This content was generated with the help of AI and it may contain mistakes
